393 related articles for article (PubMed ID: 36830839)
1. An Insight on Functioning Pancreatic Neuroendocrine Neoplasms.
Bevere M; Gkountakos A; Martelli FM; Scarpa A; Luchini C; Simbolo M
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830839
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.
Qu Y; Li H; Wang X; Chen Y; Guo Q; Pei Y; Du J; Dou J; Ba J; Lv Z; Mu Y
Int J Endocrinol; 2020; 2020():1030518. PubMed ID: 33204258
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.
Uccella S; Blank A; Maragliano R; Sessa F; Perren A; La Rosa S
Endocr Pathol; 2017 Dec; 28(4):351-361. PubMed ID: 29063495
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic neuroendocrine tumors: contemporary diagnosis and management.
Parbhu SK; Adler DG
Hosp Pract (1995); 2016 Aug; 44(3):109-19. PubMed ID: 27404266
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.
Lam AK; Ishida H
Histol Histopathol; 2021 Apr; 36(4):367-382. PubMed ID: 33305819
[TBL] [Abstract][Full Text] [Related]
6. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract][Full Text] [Related]
7. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
Jiang R; Hong X; Zhao Y; Wu W
Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification.
Khanna L; Prasad SR; Sunnapwar A; Kondapaneni S; Dasyam A; Tammisetti VS; Salman U; Nazarullah A; Katabathina VS
Radiographics; 2020; 40(5):1240-1262. PubMed ID: 32795239
[TBL] [Abstract][Full Text] [Related]
9. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms.
Grolmusz VK; Kövesdi A; Borks K; Igaz P; Patócs A
Eur J Endocrinol; 2018 Oct; 179(4):219-228. PubMed ID: 30299890
[TBL] [Abstract][Full Text] [Related]
11. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database.
Yang Z; Shi G
Eur J Surg Oncol; 2022 Oct; 48(10):2181-2187. PubMed ID: 35623986
[TBL] [Abstract][Full Text] [Related]
12. Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms.
Tachibana T; Kasajima A; Aoki T; Tabata T; McNamara K; Yazdani S; Satoko S; Fujishima F; Motoi F; Unno M; Sasano H
J Steroid Biochem Mol Biol; 2020 Jul; 201():105694. PubMed ID: 32437964
[TBL] [Abstract][Full Text] [Related]
13. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
[TBL] [Abstract][Full Text] [Related]
14. [Pancreatic neuroendocrine tumors].
Burgos L; Burgos ME
Rev Med Chil; 2004 May; 132(5):627-34. PubMed ID: 15279151
[TBL] [Abstract][Full Text] [Related]
15. [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
Kianmanesh R; O'toole D; Sauvanet A; Ruszniewski P; Belghiti J
J Chir (Paris); 2005; 142(3):132-49. PubMed ID: 16142076
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
Bocchini M; Nicolini F; Severi S; Bongiovanni A; Ibrahim T; Simonetti G; Grassi I; Mazza M
Front Oncol; 2020; 10():831. PubMed ID: 32537434
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies for advanced insulinomas and glucagonomas.
Alexandraki KI; Kaltsas GA; Grozinsky-Glasberg S
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343152
[TBL] [Abstract][Full Text] [Related]
18. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
Fujimori N; Miki M; Lee L; Matsumoto K; Takamatsu Y; Takaoka T; Teramatsu K; Suehiro Y; Murakami M; Igarashi H; Oono T; Ohtsuka T; Nakamura M; Koga Y; Oda Y; Ito T; Ogawa Y
Pancreatology; 2020 Jun; 20(4):709-715. PubMed ID: 32360001
[TBL] [Abstract][Full Text] [Related]
19. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.
Palmieri LJ; Dermine S; Barré A; Dhooge M; Brezault C; Cottereau AS; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549203
[TBL] [Abstract][Full Text] [Related]
20. The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.
Meng YF; Fan ZY; Yang J; Li YZ; Liu SJ; Gao CH; Gao X; Pang CY; Zhan HX
Front Endocrinol (Lausanne); 2023; 14():1137911. PubMed ID: 37033225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
